JP2020525542A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525542A5 JP2020525542A5 JP2020520422A JP2020520422A JP2020525542A5 JP 2020525542 A5 JP2020525542 A5 JP 2020525542A5 JP 2020520422 A JP2020520422 A JP 2020520422A JP 2020520422 A JP2020520422 A JP 2020520422A JP 2020525542 A5 JP2020525542 A5 JP 2020525542A5
- Authority
- JP
- Japan
- Prior art keywords
- immune complex
- antibody
- items
- item
- complex according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022195061A JP7512361B2 (ja) | 2017-06-23 | 2022-12-06 | Ｒｏｒ１抗体免疫複合体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762524382P | 2017-06-23 | 2017-06-23 | |
| US201762524386P | 2017-06-23 | 2017-06-23 | |
| US201762524388P | 2017-06-23 | 2017-06-23 | |
| US62/524,382 | 2017-06-23 | ||
| US62/524,388 | 2017-06-23 | ||
| US62/524,386 | 2017-06-23 | ||
| PCT/US2018/039112 WO2018237335A1 (en) | 2017-06-23 | 2018-06-22 | IMMUNOCONJUGUATED ROR1 ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022195061A Division JP7512361B2 (ja) | 2017-06-23 | 2022-12-06 | Ｒｏｒ１抗体免疫複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020525542A JP2020525542A (ja) | 2020-08-27 |
| JP2020525542A5 true JP2020525542A5 (enExample) | 2021-07-26 |
| JP7245239B2 JP7245239B2 (ja) | 2023-03-23 |
Family
ID=62904676
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520422A Active JP7245239B2 (ja) | 2017-06-23 | 2018-06-22 | Ｒｏｒ１抗体免疫複合体 |
| JP2022195061A Active JP7512361B2 (ja) | 2017-06-23 | 2022-12-06 | Ｒｏｒ１抗体免疫複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022195061A Active JP7512361B2 (ja) | 2017-06-23 | 2022-12-06 | Ｒｏｒ１抗体免疫複合体 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10335496B2 (enExample) |
| EP (1) | EP3641830A1 (enExample) |
| JP (2) | JP7245239B2 (enExample) |
| KR (2) | KR102736878B1 (enExample) |
| CN (1) | CN111587124B (enExample) |
| AU (2) | AU2018289581C1 (enExample) |
| CA (1) | CA3067829A1 (enExample) |
| IL (1) | IL271575A (enExample) |
| MX (2) | MX2019015057A (enExample) |
| TW (1) | TWI804499B (enExample) |
| WO (1) | WO2018237335A1 (enExample) |
| ZA (1) | ZA201908351B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3006249A1 (en) | 2015-11-25 | 2017-06-01 | Legochem Biosciences, Inc. | Antibody-drug conjugates comprising branched linkers and methods related thereto |
| HRP20240795T1 (hr) | 2015-11-25 | 2024-09-13 | Ligachem Biosciences Inc. | Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima |
| WO2017089894A1 (en) | 2015-11-25 | 2017-06-01 | Legochem Biosciences, Inc. | Conjugates comprising peptide groups and methods related thereto |
| TWI767915B (zh) * | 2016-06-27 | 2022-06-21 | 加州大學董事會 | Ror-1與btk拮抗劑的組合 |
| IL269535B2 (en) | 2017-03-29 | 2024-11-01 | Ligachem Biosciences Inc | Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same |
| WO2018237335A1 (en) | 2017-06-23 | 2018-12-27 | VelosBio Inc. | IMMUNOCONJUGUATED ROR1 ANTIBODIES |
| GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| GB201710836D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| EP3790591A4 (en) | 2018-05-09 | 2022-05-11 | LegoChem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
| JP2022523740A (ja) | 2019-02-01 | 2022-04-26 | ベロスビオ・インコーポレイテッド | Ｒｏｒ１抗体イムノコンジュゲートによる癌の治療 |
| SG11202110131SA (en) * | 2019-03-26 | 2021-10-28 | Univ California | Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers |
| AU2020277470A1 (en) * | 2019-05-22 | 2022-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Drug conjugates and methods of using same |
| AU2020277489A1 (en) | 2019-05-23 | 2021-11-25 | VelosBio Inc. | Anti-ROR1/anti-CD3 bispecific binding molecules |
| GB201908886D0 (en) * | 2019-06-20 | 2019-08-07 | Almac Discovery Ltd | Anthracycline derivatives |
| KR20210028544A (ko) * | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
| EP4097137A4 (en) * | 2020-01-30 | 2024-04-17 | Oncternal Therapeutics, Inc. | COMBINATIONS OF EGFR INHIBITORS AND ROR1 INHIBITORS FOR THE TREATMENT OF CANCER |
| CA3166286A1 (en) | 2020-02-07 | 2021-08-12 | Jeffry D. Watkins | Anti-ror1 antibodies and compositions |
| EP4178559A4 (en) * | 2020-07-10 | 2025-03-05 | Velosbio Inc. | Novel ror1 antibody immunoconjugates |
| CA3183184A1 (en) * | 2020-07-13 | 2022-01-20 | Regeneron Pharmaceuticals, Inc. | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
| CN116209452A (zh) * | 2020-08-06 | 2023-06-02 | 赛罗斯制药有限公司 | 用于治疗aml的疗法和rara激动剂、低甲基化剂和bcl-2抑制剂的用途 |
| IL300787A (en) * | 2020-08-21 | 2023-04-01 | Resolute Science Inc | Compositions and methods for targeting tumor-associated macrophages |
| CN116390733A (zh) * | 2020-09-28 | 2023-07-04 | 纳夫罗根公司 | 用于治疗癌症的替代性格式化的抗间皮素抗体的组合物和用途 |
| US11797990B2 (en) | 2020-11-03 | 2023-10-24 | Capital One Services, Llc | Computer-based systems configured to provide multimodal ATM access via mobile devices and methods of use thereof |
| EP4298120A1 (en) | 2021-02-25 | 2024-01-03 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| AU2022227708A1 (en) * | 2021-02-25 | 2023-10-12 | Allygen Group | Targeting conjugates comprising effector molecules and uses thereof |
| WO2022178751A1 (en) * | 2021-02-25 | 2022-09-01 | Shanghai Allygen Biologics Co., Ltd. | Targeting conjugates comprising effector molecules and uses thereof |
| WO2022188652A1 (zh) | 2021-03-09 | 2022-09-15 | 四川科伦博泰生物医药股份有限公司 | Ror1结合蛋白及其用途 |
| GB2624955A (en) * | 2021-04-02 | 2024-06-05 | Matrivax Inc | Methods and compositions for treating Clostridiodes Difficile infections |
| JP2024521629A (ja) | 2021-06-02 | 2024-06-04 | シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド | 抗体薬物コンジュゲート、及びその調製方法及びその使用 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| AU2022376953A1 (en) | 2021-10-28 | 2024-05-02 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
| KR20240125944A (ko) | 2021-12-28 | 2024-08-20 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항-ror1 항체 및 항-ror1 항체 약물 접합체 및 이의 의약적 용도 |
| US11446286B1 (en) | 2022-02-28 | 2022-09-20 | King Faisal University | Treatment of fungal infections using dabigatran etexilate |
| CN114605493B (zh) * | 2022-04-06 | 2024-06-04 | 联宁（苏州）生物制药有限公司 | 一种抗体偶联药物中间体set0526的合成方法 |
| WO2023196958A2 (en) * | 2022-04-07 | 2023-10-12 | Oncolinx Pharmaceuticals | Tumor and cancer targeting compounds |
| CN114874287B (zh) * | 2022-05-20 | 2024-04-02 | 联宁（苏州）生物制药有限公司 | 一种抗体偶联药物-连接子lnd1042的合成方法 |
| CA3259758A1 (en) | 2022-06-30 | 2024-01-04 | Sutro Biopharma Inc | Anti-ROR1 antibodies and antibody conjugates, compositions comprising anti-ROR1 antibodies or antibody conjugates, and methods of manufacturing and using anti-ROR1 antibodies and antibody conjugates |
| JP2025526427A (ja) | 2022-07-26 | 2025-08-13 | エイムド バイオ インコーポレイテッド | 抗ｒｏｒ１抗体及びその用途 |
| CN119907807A (zh) * | 2022-08-11 | 2025-04-29 | 翰森生物有限责任公司 | 配体-细胞毒性药物偶联物及其药物用途 |
| CN117624167A (zh) * | 2022-08-18 | 2024-03-01 | 四川大学 | 吡咯并苯并二氮杂卓-蒽酰亚胺杂交分子及其制备方法和用途 |
| CN115806630A (zh) * | 2022-08-23 | 2023-03-17 | 上海交通大学 | 用于肿瘤免疫/靶向性治疗的pd-1蛋白-细胞毒素偶联物及其制备方法、应用 |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| KR20250110926A (ko) * | 2022-11-30 | 2025-07-21 | 머크 샤프 앤드 돔 엘엘씨 | Ror1 항체 면역접합체 및 btk 억제제를 사용하는 암 치료 |
| WO2024186263A1 (en) | 2023-03-07 | 2024-09-12 | Axcynsis Therapeutics Pte. Ltd. | Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives |
| WO2024213040A1 (zh) * | 2023-04-11 | 2024-10-17 | 浙江博锐生物制药有限公司 | 抗ror1抗体及其药物偶联物 |
| CN120957756A (zh) * | 2023-05-12 | 2025-11-14 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物及其制备方法和用途 |
| CN119744272A (zh) * | 2023-07-31 | 2025-04-01 | 石药集团巨石生物制药有限公司 | 一种抗ror1蛋白的抗体及其缀合物 |
| WO2025029920A1 (en) * | 2023-08-01 | 2025-02-06 | Oncternal Therapeutics, Inc. | Glycoengineered forms of ror1 antibodies and methods of use |
| WO2025083071A2 (en) * | 2023-10-16 | 2025-04-24 | Hummingbird Bioscience Pte. Ltd. | Antibody-drug conjugates |
| WO2025083185A1 (en) | 2023-10-20 | 2025-04-24 | Athebio Ag | Reducing off-target accumulation of targeted pharmaceutical compounds |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| GB9816575D0 (en) | 1998-07-31 | 1998-09-30 | Zeneca Ltd | Novel compounds |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ES2456325T3 (es) | 2003-11-06 | 2014-04-22 | Seattle Genetics, Inc. | Compuestos de monometilvalina capaces de conjugación con ligandos |
| US8288352B2 (en) | 2004-11-12 | 2012-10-16 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
| WO2007051077A2 (en) | 2005-10-28 | 2007-05-03 | The Regents Of The University Of California | Methods and compounds for lymphoma cell detection and isolation |
| AR060978A1 (es) * | 2006-05-30 | 2008-07-23 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos |
| WO2007143212A1 (en) * | 2006-06-02 | 2007-12-13 | Ariad Gene Therapeutics, Inc. | Capecitabine combination therapy |
| US20090258442A1 (en) | 2006-08-31 | 2009-10-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| ES2547552T3 (es) | 2008-02-01 | 2015-10-07 | Genentech, Inc. | Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos |
| US8609105B2 (en) | 2008-03-18 | 2013-12-17 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| JP2011525535A (ja) * | 2008-06-24 | 2011-09-22 | 武田薬品工業株式会社 | ＰＩ３Ｋ／ｍＴＯＲ阻害剤 |
| WO2010009124A2 (en) | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| BRPI1012560A2 (pt) * | 2009-04-01 | 2016-07-26 | Genentech Inc | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso |
| CA2759733C (en) * | 2009-04-23 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
| US20120282177A1 (en) | 2009-11-02 | 2012-11-08 | Christian Rohlff | ROR1 as Therapeutic and Diagnostic Target |
| ES2635316T3 (es) | 2009-12-18 | 2017-10-03 | Kancera Ab | Anticuerpos contra ROR1 que pueden inducir muerte celular de LLC |
| ES2623057T3 (es) | 2010-04-15 | 2017-07-10 | Medimmune Limited | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas |
| CN103068405A (zh) | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| WO2011154542A1 (en) | 2010-06-11 | 2011-12-15 | Artisense Pharma Gmbh | Method for selective oligonucleotide modification |
| US9242014B2 (en) | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| EP2621954A1 (en) | 2010-10-01 | 2013-08-07 | Oxford Biotherapeutics Ltd. | Anti-rori antibodies |
| AU2011336650B2 (en) | 2010-12-01 | 2016-12-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ROR1 antibodies |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| DK2663579T3 (en) | 2011-01-14 | 2017-07-31 | Univ California | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| US20130131139A1 (en) | 2011-11-17 | 2013-05-23 | Oregon Health & Science University | Ror1 as a gene target in acute lymphoblastic leukemia |
| WO2013121175A1 (en) | 2012-02-16 | 2013-08-22 | Ucl Business Plc | Lysosome-cleavable linker |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| WO2014031171A1 (en) | 2012-08-20 | 2014-02-27 | President And Fellows Of Harvard College | Use of nanowires for delivering biological effectors into immune cells |
| WO2014031174A1 (en) * | 2012-08-24 | 2014-02-27 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| RS58921B1 (sr) | 2012-10-12 | 2019-08-30 | Medimmune Ltd | Pirolobenzodiazepini i njihovi konjugati |
| JP6133431B2 (ja) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
| PT2935259T (pt) | 2012-12-21 | 2019-04-04 | Abgenomics Int Inc | Ligantes de autoimolação hidrofílicos e conjugados dos mesmos |
| WO2014140300A1 (en) | 2013-03-15 | 2014-09-18 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
| EP2968593B1 (en) | 2013-03-15 | 2024-11-20 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| US9295731B2 (en) | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| US20180104349A9 (en) | 2013-04-28 | 2018-04-19 | Gang Qin | Novel linker, preparation method, and application thereof |
| WO2014197854A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
| JP6208864B2 (ja) * | 2013-06-24 | 2017-10-04 | エービーエルバイオ | 安定性が改善された抗体−薬物結合体およびこれの用途 |
| ES2809501T3 (es) * | 2013-07-05 | 2021-03-04 | Formation Biologics Inc | Conjugados de anticuerpo de EGFR |
| WO2015038426A1 (en) | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
| IL245009B (en) | 2013-10-11 | 2022-08-01 | Asana Biosciences Llc | Protein-polymer-drug conjugates |
| JP6747971B2 (ja) | 2013-10-15 | 2020-08-26 | シアトル ジェネティックス， インコーポレイテッド | 改善されたリガンド−薬物コンジュゲート薬物動態のためのｐｅｇ化薬物−リンカー |
| WO2015146550A1 (ja) * | 2014-03-24 | 2015-10-01 | 株式会社ジーシー | ２ペースト重合性組成物 |
| US20170196888A1 (en) | 2014-06-25 | 2017-07-13 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer |
| CA2953164C (en) * | 2014-07-22 | 2023-04-11 | Iogen Corporation | Process for producing fuel using two fermentations |
| CA2963692A1 (en) | 2014-10-09 | 2016-04-14 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 |
| JP2017536341A (ja) | 2014-10-09 | 2017-12-07 | エンクマフ アーゲー | 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体 |
| WO2016094873A2 (en) | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| KR20170128234A (ko) * | 2015-01-16 | 2017-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ror1에 특이적인 항체 및 키메라 항원 수용체 |
| HK1253507A1 (zh) | 2015-05-18 | 2019-06-21 | Eureka Therapeutics, Inc. | 抗 ror1 抗體 |
| KR20180069067A (ko) * | 2015-10-30 | 2018-06-22 | 엔비이-테라퓨틱스 아게 | 안티-ror1 항체 |
| CN108848669B (zh) * | 2016-01-20 | 2022-06-07 | 斯克利普斯研究所 | Ror1抗体组合物和相关方法 |
| CA3011419A1 (en) | 2016-01-22 | 2017-07-27 | Janssen Biotech, Inc. | Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same |
| TWI767915B (zh) | 2016-06-27 | 2022-06-21 | 加州大學董事會 | Ror-1與btk拮抗劑的組合 |
| US20200338210A1 (en) * | 2016-12-22 | 2020-10-29 | Ardeagen Corporation | Anti-ror1 antibody and conjugates thereof |
| WO2018237335A1 (en) * | 2017-06-23 | 2018-12-27 | VelosBio Inc. | IMMUNOCONJUGUATED ROR1 ANTIBODIES |
| JP2022523740A (ja) | 2019-02-01 | 2022-04-26 | ベロスビオ・インコーポレイテッド | Ｒｏｒ１抗体イムノコンジュゲートによる癌の治療 |
-
2018
- 2018-06-22 WO PCT/US2018/039112 patent/WO2018237335A1/en not_active Ceased
- 2018-06-22 JP JP2020520422A patent/JP7245239B2/ja active Active
- 2018-06-22 TW TW107121603A patent/TWI804499B/zh active
- 2018-06-22 KR KR1020207001376A patent/KR102736878B1/ko active Active
- 2018-06-22 MX MX2019015057A patent/MX2019015057A/es unknown
- 2018-06-22 CN CN201880052547.2A patent/CN111587124B/zh active Active
- 2018-06-22 AU AU2018289581A patent/AU2018289581C1/en active Active
- 2018-06-22 CA CA3067829A patent/CA3067829A1/en active Pending
- 2018-06-22 KR KR1020217019380A patent/KR20210079427A/ko active Pending
- 2018-06-22 EP EP18740488.4A patent/EP3641830A1/en active Pending
- 2018-07-05 US US16/027,967 patent/US10335496B2/en not_active Ceased
-
2019
- 2019-04-05 US US16/376,238 patent/US20200030454A1/en not_active Abandoned
- 2019-12-13 MX MX2021007620A patent/MX2021007620A/es unknown
- 2019-12-13 ZA ZA2019/08351A patent/ZA201908351B/en unknown
- 2019-12-19 IL IL271575A patent/IL271575A/en unknown
-
2021
- 2021-07-01 US US17/365,293 patent/USRE50631E1/en active Active
- 2021-11-11 US US17/524,511 patent/US20220133901A1/en active Pending
-
2022
- 2022-12-06 JP JP2022195061A patent/JP7512361B2/ja active Active
-
2024
- 2024-10-18 AU AU2024227446A patent/AU2024227446A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020525542A5 (enExample) | ||
| JP7512361B2 (ja) | Ｒｏｒ１抗体免疫複合体 | |
| JP2018525354A5 (enExample) | ||
| JP2024075668A (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| HRP20200551T1 (hr) | Axl-specifični konjugati protutijelo-lijek za liječenje raka | |
| CN110240654A (zh) | 结合cd73的抗体-药物偶联物 | |
| JP2012522513A5 (enExample) | ||
| JP7735490B2 (ja) | 抗１９１ｐ４ｄ１２抗体薬物コンジュゲートを含む薬学的組成物、およびその使用方法 | |
| JP2023113685A (ja) | 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| CN110845616A (zh) | 抗-egfr抗体及抗体药物偶联物 | |
| JP2017522871A5 (enExample) | ||
| JPWO2021213434A5 (enExample) | ||
| CA3093731A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| CN110575548A (zh) | 靶向于cd73的抗体-药物偶联物及其制法和用途 | |
| US11110179B2 (en) | Combination of CD33 antibody drug conjugates with chemotherapeutic agents | |
| KR20250137203A (ko) | 항체 약물 접합체 | |
| JP7446341B2 (ja) | 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| JPWO2020161214A5 (enExample) | ||
| JP7594708B1 (ja) | ネクチン４を標的としエキサテカンペイロードを含む抗体薬物コンジュゲート（ａｄｃ） | |
| Davidkova et al. | Mechanisms of resistance of antibody-drug conjugates—Obstacles to overcome | |
| CN121079107A (zh) | 一种连接子、抗体药物偶联物及其制备方法 | |
| CN120923577A (zh) | 大环类药物偶联物及其制备方法和用途 | |
| IL318911A (en) | Humanized antibodies against NECTIN-4 and their drug conjugates | |
| CN120957755A (zh) | 多环类药物偶联物及其制备方法和用途 | |
| BR112019027448B1 (pt) | Imunoconjugado compreendendo um anticorpo conjugado a uma porção de fármaco citotóxica, composição farmacêutica e uso dos mesmos |